Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 2
2017 1
2018 1
2019 1
2020 1
2021 1
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taïeb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, Bouvier-Morel E, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, Borget I. Leboulleux S, et al. Among authors: anizan n. Clin Cancer Res. 2023 Jul 5;29(13):2401-2409. doi: 10.1158/1078-0432.CCR-23-0046. Clin Cancer Res. 2023. PMID: 37074727 Clinical Trial.
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer.
Leboulleux S, Benisvy D, Taieb D, Attard M, Bournaud C, Terroir-Cassou-Mounat M, Lacroix L, Anizan N, Schiazza A, Garcia ME, Ghuzlan AA, Lamartina L, Schlumberger M, Godbert Y, Borget I. Leboulleux S, et al. Among authors: anizan n. Thyroid. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26. Thyroid. 2023. PMID: 37350119 Clinical Trial. No abstract available.
Nanostructured lipid carriers accumulate in atherosclerotic plaques of ApoE-/- mice.
Vigne J, Cabella C, Dézsi L, Rustique E, Couffin AC, Aid R, Anizan N, Chauvierre C, Letourneur D, Le Guludec D, Rouzet F, Hyafil F, Mészáros T, Fülöp T, Szebeni J, Cordaro A, Oliva P, Mourier V, Texier I. Vigne J, et al. Among authors: anizan n. Nanomedicine. 2020 Apr;25:102157. doi: 10.1016/j.nano.2020.102157. Epub 2020 Jan 23. Nanomedicine. 2020. PMID: 31982616
Cleaved CD31 as a target for in vivo molecular imaging of inflammation.
Vigne J, Bay S, Aid-Launais R, Pariscoat G, Rucher G, Sénémaud J, Truffier A, Anizan N, Even G, Ganneau C, Andreata F, Le Borgne M, Nicoletti A, Le Guludec D, Caligiuri G, Rouzet F. Vigne J, et al. Among authors: anizan n. Sci Rep. 2019 Dec 20;9(1):19560. doi: 10.1038/s41598-019-56163-x. Sci Rep. 2019. PMID: 31863037 Free PMC article.
Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept.
Varasteh Z, Hyafil F, Anizan N, Diallo D, Aid-Launais R, Mohanta S, Li Y, Braeuer M, Steiger K, Vigne J, Qin Z, Nekolla SG, Fabre JE, Döring Y, Le Guludec D, Habenicht A, Vera DR, Schwaiger M. Varasteh Z, et al. Among authors: anizan n. EJNMMI Res. 2017 Dec;7(1):40. doi: 10.1186/s13550-017-0287-y. Epub 2017 May 3. EJNMMI Res. 2017. PMID: 28470406 Free PMC article.
12 results